Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINA3 | P01011 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24824202 | 1.00 | SERPINA3 (0.51) | SERPINA3NT5ECYP3A4CYP2C9CA5A | |
| SCHEMBL25542556 | 1.00 | SERPINA3 (0.51) | SERPINA3NT5ECYP3A4CYP2C9CA5A | |
| SCHEMBL25542537 | 1.00 | SERPINA3 (0.51) | SERPINA3NT5ECYP3A4CYP2C9CA5A | |
| SCHEMBL29830757 | 1.00 | SERPINA3 (0.51) | SERPINA3NT5ECYP3A4CYP2C9CA5A | |
| SCHEMBL30335218 | 1.00 | SERPINA3 (0.51) | SERPINA3NT5ECYP3A4CYP2C9CA5A | |
| SCHEMBL29830722 | 0.96 | SERPINA3 (0.46) | SERPINA3NT5ECYP3A4CYP2C9CA5A | |
| SCHEMBL24824204 | 0.94 | SERPINA3 (0.42) | SERPINA3NT5ECA5AADORA3ADORA2A | |
| SCHEMBL27134890 | 0.93 | SERPINA3 (0.43) | SERPINA3NT5ECA5AADORA3ADORA2A | |
| SCHEMBL26977115 | 0.93 | SERPINA3 (0.43) | SERPINA3NT5ECA5AADORA3ADORA2A | |
| SCHEMBL24824237 | 0.93 | SERPINA3 (0.42) | SERPINA3NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182510-A1 | Compounds Useful in HIV Treatment | VIIV HEALTHCARE COMPANY (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4298105-A1 | COMPOUNDS USEFUL IN HIV TREATMENT | VIIV Healthcare Company (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022182604-A1 | COMPOUNDS USEFUL IN HIV TREATMENT | VIIV HEALTHCARE COMPANY (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | SERPINA3 304/4885NT5E 1724/4885CYP3A4 136/4885 |
| US-20240182510-A1 | Compounds Useful in HIV Treatment | CCR5, G6PD, NPC1 | SERPINA3 385/4885NT5E 1796/4885CYP3A4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.